新京报讯（记者张秀兰）12月22日，原发性胆汁性胆管炎（PBC）药物Seladelpar在海南博鳌乐城国际 医疗旅游先行区获批，适用于与熊去氧胆酸（UDCA）联合治疗对UDCA单药应答不佳的PBC成人患 者，或作为单药用于治疗无法耐受UDCA的PBC成人患者。该药也是全球首个获批用于治疗原发性胆汁 性胆管炎的强效选择性过氧化物酶体增殖物激活受体δ（PPARδ）激动剂。 原发性胆汁性胆管炎已被纳入我国第二批罕见病目录。数据显示，中国PBC患病率为20.5/10万，该病好 发于中老年女性，男女比例约为1:9，近年来男性患者比例也有所增加。谢青指出，随着诊断水平提升 以及临床医生关注度提高，越来越多的PBC患者在肝功能生化指标的常规体检中被发现，但目前我国尚 缺乏基于全国人群的大规模流行病学调查数据，实际发病率可能仍被低估。 长期以来，以熊去氧胆酸（UDCA）为主的一线治疗方案难以满足患者的治疗需求，近40%的患者应答 不佳，这部分患者疾病进展风险高，可以进展为失代偿期肝硬化、肝衰竭，甚至需要肝移植治疗。与此 同时，传统治疗对瘙痒症状改善有限。谢青表示，Seladelpar以其独特的作用机制为原发性胆汁性胆管 炎的 ...

12月23日，联合国安理会在有关国家强行推动下就伊朗核问题举行公开会。伊朗代表则在会上对中国和 俄罗斯在伊核问题全面协议实施过程中所秉持的原则立场，以及忠实履行承诺表示感谢。 编辑张锦嫣制作礼牧周 ...

目前暂无人员伤亡报告，在对受损区域进行必要的安全检查后，该船继续航行。 编辑易向荃制作高晨曦 12月23日，土耳其一艘货轮在黑海遭一架无人机袭击，船员用手机拍下货轮内的混乱画面。 报道称，袭击引发火灾，驾驶室内一片混乱，窗外被浓烟弥漫。由于船员反应迅速且协调一致，火情很 快得到控制。 ...

眼下，聚酯纤维已经成为重要的服饰面料。然而最近，"一身塑料过冬"的话题在网络上引发热议，甚至 被调侃成了穷人的名片。有短视频把废弃饮料瓶加热融化拉丝，配上发现新大陆一样震惊的声音："看 塑料瓶拉的丝，咱身上的衣服就是拿它做的！" 由此，有人在互联网上调侃："富人穿羊绒真丝，中产穿棉麻，打工人一身聚酯纤维。"由此，聚酯纤维 不仅被简化为廉价材料的代名词，也在这种戏谑中被强行拉进了一条格外刺眼的消费鄙视链里。 当然，不同事物不见得可以一概而论，但聚酯纤维确实像被冤枉的。而且人们还应当对聚酯纤维抱有特 别的"感情"——聚酯纤维因其良好的性价比，极大解决了"丰衣"的问题。正如专家所言，"聚酯纤维的 出现，曾经为解决我国乃至全球穿衣短缺问题做出过重要贡献。" 正是聚酯纤维的大范围应用，才让"穿衣自由"成为多数人的日常现实。与其说它代表了"低端"，不如说 它恰恰是现代工业将技术红利普遍化的结果，它才是某种意义上的人类智慧结晶。 值得注意的是，我国在材料方面还处于世界领先的位置。前几天发布的《面向未来产业的工程科技2025 （新材料）》显示，根据2021年至2025年QS世界大学学科排名数据（由英国国际教育市场咨询公司QS ...

▲很多被改造的聚酯纤维，性能远在所谓天然材料之上，也绝非塑料可比。图/湖北经视直播 眼下，聚酯纤维已经成为重要的服饰面料。然而最近，"一身塑料过冬"的话题在网络上引发热议，甚至被调侃成 了穷人的名片。有短视频把废弃饮料瓶加热融化拉丝，配上发现新大陆（000997）一样震惊的声音："看塑料瓶拉 的丝，咱身上的衣服就是拿它做的！" 由此，有人在互联网上调侃："富人穿羊绒真丝，中产穿棉麻，打工人一身聚酯纤维。"由此，聚酯纤维不仅被简 化为廉价材料的代名词，也在这种戏谑中被强行拉进了一条格外刺眼的消费鄙视链里。 似乎只要是名字带有一些非传统的"化学词汇"，就天然被贴上了"不健康""不自然"的标签，被迅速纳入怀疑与排 斥的序列之中。而复杂的生产逻辑、具体的剂量标准，反倒在这种情绪化判断里被轻易忽略了。 当然，不同事物不见得可以一概而论，但聚酯纤维确实像被冤枉的。而且人们还应当对聚酯纤维抱有特别的"感 情"——聚酯纤维因其良好的性价比，极大解决了"丰衣"的问题。正如专家所言，"聚酯纤维的出现，曾经为解决 我国乃至全球穿衣短缺问题做出过重要贡献。" 正是聚酯纤维的大范围应用，才让"穿衣自由"成为多数人的日常现实。与其说它代 ...

12月23日，土耳其一艘货轮在黑海遭一架无人机袭击，船员用手机拍下货轮内的混乱画面。报道称，袭 击引发火灾，驾驶室内一片混乱，窗外被浓烟弥漫。由于船员反应迅速且协调一致，火情很快得到控 制。目前暂无人员伤亡报告，在对受损区域进行必要的安全检查后，该船继续航行。 ...

Core Viewpoint - Future Health, the parent company of the popular massage device brand SKG, is attempting to enter the capital market through the Hong Kong Stock Exchange after two failed attempts to list on the A-share market. The company has shown steady profit growth over the past three years, with a gross margin of around 50%, significantly higher than typical home appliances. However, concerns arise from its heavy reliance on marketing over research and development, as well as its financial practices of high dividends alongside increasing debt [1][2]. Group 1: Company Performance and Financials - Future Health was established in November 2007 and has made multiple attempts to list on the A-share market, including a withdrawal of its application in August 2023. The company plans to list on the North Exchange after being delisted from the New Third Board in November 2023 [2]. - The company reported revenues of 904 million yuan, 1.046 billion yuan, and 1.045 billion yuan for the years 2022, 2023, and 2024 respectively, with net profits of 119 million yuan, 127 million yuan, and 135 million yuan for the same years. In the first nine months of 2025, it achieved revenue of 878 million yuan and a net profit of 106 million yuan [2]. - Future Health's gross margins for 2022, 2023, and 2024 were 50.4%, 49.1%, and 48.9% respectively, indicating strong profitability compared to other appliance categories [5]. Group 2: Marketing and R&D Strategy - The company has increasingly focused on marketing, with marketing expenses rising to 22.6% of total revenue by 2025, while R&D spending has decreased to 6.6% of revenue [1][7]. - Future Health's marketing strategy includes partnerships with celebrities and influencers, utilizing platforms like Douyin and Xiaohongshu to enhance user engagement and brand loyalty [6][8]. Group 3: Financial Practices and Governance - Prior to its IPO, Future Health distributed a total of 280 million yuan in dividends, which accounted for 74% of its net profit during that period. This included a significant dividend payout of 199.4 million yuan in the first nine months of 2025 [8]. - The company's debt increased from 94 million yuan at the end of 2022 to 204 million yuan by September 2025, raising concerns about its financial management practices, particularly the juxtaposition of high dividends and rising debt [8].

快手音乐的内容嗅觉和宣发策略给市场带来了确定性。 近日，在【声·势】快手音乐生态大会（下称：大会）上，快手音乐、快手大数据研究院联合中国音像 与数字出版协会数字音乐工作委员会发布了《2025快手音乐生态数据报告》（下称：《报告》）。报告 显示，2025年，平台推出105首自制歌曲，量身定制艺人企划10首；其中大热歌曲《弥渡山歌 （PHONK）》累计登上流媒体热歌榜超百日，成为现象级音乐作品。 目前，快手音乐正通过即时捕捉内容趋势风向，结合平台情绪、内容热点，加上宣推创意策划 ，塑造 自己的音乐宣发策略。而这套热歌方法论也给行业推歌成本高转化难、玩法内卷等痛点提供了破局思 路。快手音乐中心负责人于蓝透露，2025年，快手音乐「π」计划项目组与行业内超过130家音乐公司 或厂牌合作，策划宣推歌曲超370首。 面向2026年，快手音乐宣发策略进一步升级。在快手音乐宣推平台方面，平台全年将投入亿级流量及核 心资源位，采用定制化分配机制适配不同歌曲推广需求，聚焦节假日及特定曲风推出"快闪"优惠活动。 在IP（知识产权）规划上，快手将推动"巡乐环游记"与"快手音乐班"两大IP规模化、品牌化；还将扩容 线下场景，从单一歌会 ...

Core Viewpoint - The company Future Health is attempting to go public on the Hong Kong Stock Exchange after unsuccessful attempts to list on the A-share market, highlighting concerns over its marketing-heavy strategy and low R&D investment [1][2]. Group 1: Company Performance - Future Health has shown steady net profit growth over the past three years, with high gross margins around 50%, significantly exceeding typical household appliance margins [1][5]. - The company's revenue for 2022, 2023, and 2024 is reported at 904 million, 1.046 billion, and 1.045 billion respectively, with net profits of 119 million, 127 million, and 135 million [2]. - In the first nine months of 2025, the company achieved a revenue of 878 million and a net profit of 106 million [2]. Group 2: Marketing and R&D Strategy - Future Health's marketing expenses have increased, accounting for 22.6% of revenue, while R&D investment has decreased to 6.6% [1][7]. - The company relies heavily on online sales channels, which contributed 60.2% of its revenue in 2022, decreasing to 49.3% by 2025 [6]. - The company employs various marketing strategies, including celebrity endorsements and social media engagement, with marketing expenses rising from 1.64 billion in 2022 to 1.98 billion in the first nine months of 2025 [6][7]. Group 3: Financial Practices and Concerns - Future Health has distributed a total of 280 million in dividends prior to its IPO, raising concerns about its financial practices, especially as it simultaneously increased its debt from 94 million to 204 million [8]. - The company's ownership structure is heavily concentrated, with the founders controlling over 85% of the voting rights, leading to questions about governance and financial transparency [8]. Group 4: Industry Context - The wearable health device market in China is projected to grow from 30.9 billion in 2019 to 61.5 billion by 2024, with a compound annual growth rate of 15.9% expected from 2024 to 2029 [3]. - Future Health is positioned as a leader in the smart wearable health device sector, holding a 21.5% market share in 2024 [2]. - The competitive landscape is characterized by a focus on technology and market segmentation, with leading companies holding over 25% of the market share [4].

良品铺子的"卖身"路 良品铺子（603719）的股权"卖给谁"又增添变数。休闲食品企业良品铺子发布公告称，控股股东宁波汉 意创业投资合伙企业(有限合伙)(简称"宁波汉意")收到法院通知，原告广州轻工工贸集团有限公司(简 称"广州轻工")要求变更诉讼请求为解除原签署的股权转让相关协议，并要求被告支付违约金等各类费 用超2000万元。 今年7月，良品铺子突发公告称，引入武汉国资旗下企业作为战略投资者并成为公司未来新的控股股 东。此次交易，良品铺子认为是企业长期发展战略的主动选择，通过引入本地国资，公司将在供应链优 化、渠道拓展、研发创新等领域实现突破。不过后续良品铺子被广州轻工告上法庭，原因在于，良品铺 子方面与武汉金融控股(集团)有限公司旗下武汉长江国际贸易集团有限公司(简称"长江国贸")签署转让 协议前，就已经与广州轻工方面进行了接触，但未能签署协议。但从此次变更来看，广州轻工不再执着 于良品铺子的股权，转而投向了寻求赔偿。从良品铺子来看，这一次或许可以真的投入到武汉国资 的"怀抱"了。 广州轻工变更请求 广州轻工与宁波汉意的纠纷一波三折。 根据良品铺子公布的最新信息显示，宁波汉意近日收到广州中院送达的《关于 ...